Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 5 wks
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)
Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.